top of page

Brushing up on the science of obesity with Rhythm Pharmaceuticals’ CEO

David Meeker describes his company’s focus on the melanocortin-4 receptor pathway and elaborates on data presented this week for hypothalamic obesity.



Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page